For more than 20 years, Medicare was legally barred from covering prescription drugs prescribed solely for weight loss. That ban ends July 1, 2026. Starting that date, Medicare Part D will cover Wegovy and Zepbound for obesity treatment through a program called the Medicare GLP-1 Bridge, at a flat $50 per month copay.
This is a real change that will matter to millions of people on Medicare. But it comes with restrictions that are easy to miss, and the details determine whether you actually qualify.
Key Takeaways
- The Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027.
- Covered drugs: Wegovy (injection and pill) and Zepbound. Ozempic and Mounjaro are not covered under this program.
- Copay is $50/month flat, regardless of where you are in your Part D benefit phase.
- You must be enrolled in Medicare Part D and meet specific BMI criteria.
- Prior authorization is required. Your provider submits it on your behalf.
- The $50 copay does not count toward your Part D deductible or the $2,100 annual out-of-pocket cap. Low-income subsidies do not apply.
What Changed, and Why
Traditional Medicare has excluded weight loss medications since the program's creation. Congress explicitly wrote that exclusion into law. Legislation like the Treat and Reduce Obesity Act has pushed to overturn it for years, with bipartisan support but slow progress.
The GLP-1 Bridge is a different mechanism: a CMS-run demonstration program that sidesteps the statutory exclusion by operating outside the normal Part D formulary structure. Participating drug manufacturers (Novo Nordisk for Wegovy and Eli Lilly for Zepbound) agreed to supply the medications at a net price of $245 per month, enabling the $50 copay for beneficiaries. The original program was supposed to run only through the end of 2026; on April 21, 2026, CMS extended it through December 31, 2027.
Whatever legislative pathway eventually makes this permanent, the practical result for beneficiaries is the same: Medicare is covering these drugs for obesity, for the first time, starting this summer.
Who Qualifies
You must be enrolled in Medicare Part D. Beyond that, eligibility hinges on BMI and, in some cases, a qualifying health condition. Your provider will submit a prior authorization request attesting that you meet one of these three criteria:
BMI 35 or higher (no additional condition required)
If your BMI is 35 or above, you qualify based on BMI alone. You do not need a separate diagnosis to access the bridge program. Use our BMI calculator to check where you stand.
BMI 27 or higher with one of these conditions
- Pre-diabetes (by American Diabetes Association guidelines)
- Previous heart attack
- Previous stroke
- Symptomatic peripheral artery disease
BMI 30 or higher with one of these conditions
- Heart failure with preserved ejection fraction
- Uncontrolled hypertension (systolic above 140 or diastolic above 90, despite two antihypertensive medications)
- Chronic kidney disease, stage 3a or above
These criteria are tighter than the standard FDA labeling for Wegovy and Zepbound, which allows prescribing at BMI 30+ or 27+ with any weight-related condition. If your BMI is between 27 and 34 and you don't have one of the listed conditions, you won't qualify for the bridge program, even if a doctor would otherwise prescribe the medication.
What It Actually Costs
The copay is $50 per month, flat. It doesn't change based on which Part D phase you're in (deductible phase, coverage gap, catastrophic coverage: it's always $50).
There are a few things that make this less straightforward than it sounds. The $50 does not count toward your Part D deductible or your annual $2,100 out-of-pocket spending cap. So if you're already managing other prescription costs through Part D, the bridge program's copay exists in its own accounting lane. It won't help you reach your out-of-pocket limit faster.
Low-income subsidy (LIS/Extra Help) benefits do not apply to the bridge program copay either. For beneficiaries who rely on those subsidies to manage medication costs, that's a meaningful limitation. You'll pay $50 regardless of income.
To put it in context: retail price for Wegovy without insurance runs roughly $1,000 to $1,300 per month. The bridge program's net drug price is $245, with the government and manufacturer absorbing the rest. At $50 out of pocket, most Medicare beneficiaries who qualify will pay less for Wegovy or Zepbound than most commercially insured patients are currently paying.
Which Drugs Are Covered (and Which Aren't)
The Medicare GLP-1 Bridge covers three products when prescribed specifically for weight reduction:
- Wegovy (semaglutide injection, weekly)
- Wegovy tablets (the oral semaglutide pill approved in early 2026)
- Zepbound KwikPen (tirzepatide injection, weekly)
- Foundayo (a new Novo Nordisk product for weight reduction)
Ozempic is not covered under the bridge program. Ozempic (semaglutide) is FDA-approved for type 2 diabetes, and Medicare Part D already covers it for that indication through standard formulary coverage. If you're on Ozempic for diabetes, that prescription stays on your Part D plan as before. You don't move it to the bridge. If you don't have diabetes and want semaglutide for weight loss, Wegovy is the correct drug to ask for.
Mounjaro is also not covered under the bridge. Like Ozempic, Mounjaro (tirzepatide) is approved for type 2 diabetes and is covered through standard Part D for that use. Zepbound is the tirzepatide product approved for weight management, and Zepbound is what the bridge covers.
This distinction isn't just regulatory housekeeping. It matters when you talk to your doctor. If you ask for Ozempic for weight loss, you're asking for something the bridge doesn't cover and that most Medicare plans won't pay for outside a diabetes diagnosis. Ask for Wegovy or Zepbound.
What You Need to Do
The process runs through your prescribing provider, not through Medicare directly. Here's how it works in practice:
- Talk to your doctor or a weight loss clinic. Tell them you want to pursue the Medicare GLP-1 Bridge program starting July 1. Make sure they're familiar with it. Not every provider has caught up yet.
- Confirm you meet the eligibility criteria. BMI documentation and any qualifying diagnoses will be part of the prior authorization paperwork.
- Your provider submits a prior authorization. This goes to your Part D plan. The authorization attests that you meet the bridge program's BMI and medical criteria and that the prescription is for weight reduction, not for a diabetes or cardiovascular indication.
- Fill the prescription at a participating pharmacy. Your Part D plan manages the bridge enrollment on the back end. You pay the $50 copay at the pharmacy counter.
If you don't currently have a provider who prescribes GLP-1 medications, now is a good time to find one. The program starts July 1, and prior authorization processing takes time. Getting the appointment scheduled in May or June puts you in position to have coverage from day one. Find a GLP-1 clinic near you that accepts Medicare patients, or check your state's Medicare coverage details.
What If You're Already on a GLP-1 for Diabetes?
If Medicare Part D is already covering Ozempic or Mounjaro for your type 2 diabetes, nothing changes. You stay on your current Part D formulary coverage for that indication. The bridge program only applies when the prescription is specifically for weight reduction. You can't switch to the bridge to get a lower copay on a drug you're already receiving for a different covered condition.
Frequently Asked Questions
Does Medicare cover Ozempic for weight loss?
No. Ozempic is covered by Medicare Part D for type 2 diabetes. If your only reason for wanting Ozempic is weight loss and you don't have a diabetes diagnosis, Medicare won't cover it under the bridge program or standard Part D. The weight-loss-approved version of semaglutide is Wegovy, which is covered under the bridge starting July 1.
Does Medicare cover Mounjaro for weight loss?
No. Mounjaro is FDA-approved for type 2 diabetes, and that's how Medicare covers it. Zepbound is the tirzepatide product approved for weight management, and Zepbound is what the bridge covers. If your doctor prescribes Mounjaro and codes it as weight loss, it won't go through the bridge program.
What if my BMI is 29 and I don't have any of the listed conditions?
You won't qualify for the bridge program as written. The lowest BMI threshold with no additional condition is 35. At BMI 27 to 34, you need one of the specific qualifying diagnoses. This is stricter than standard prescribing criteria, where BMI 30+ with any comorbidity is enough.
Will this coverage be permanent?
Not yet. The bridge is a demonstration program running through December 2027. CMS extended it in April 2026, which suggests some commitment to keeping it going, but permanent statutory coverage would require Congress to change the law that excludes weight loss medications from standard Medicare coverage. That legislation exists (the Treat and Reduce Obesity Act) but has not passed as of May 2026.
Can Medicare Advantage plans participate?
The bridge is structured as a Part D program. Medicare Advantage plans with Part D benefits should be able to participate, but plan participation isn't mandatory. Contact your plan directly to confirm they're enrolling in the bridge before July 1 if you have Medicare Advantage.
I qualify. What do I say to my doctor?
Tell them you want to start Wegovy or Zepbound through the Medicare GLP-1 Bridge program beginning July 1, 2026. Bring documentation of your BMI and any qualifying conditions. Ask them to submit a prior authorization to your Part D plan. If your doctor isn't familiar with the bridge program, point them to the CMS page at cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge.
Talk to your doctor about whether GLP-1 treatment is the right fit for your health situation before starting any new medication.
Ready to find a provider? Browse GLP-1 clinics near you that accept Medicare patients, or read our Medicare GLP-1 coverage guide for state-by-state details.